Incorporation of targeted therapies such as inhibitors of epidermal growth factor receptor (EGFR) or vascular endothelial growth factor (VEGF) signaling have improved outcomes in human lung adenocarcinoma harboring sensitizing mutations (19, 20). Here, VEGFA is linked to lung adenocarcinoma.